References
- Harvey K and Tapon N (2007) The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer 7, 182-191 https://doi.org/10.1038/nrc2070
- Meignin C, Alvarez-Garcia I, Davis I and Palacios IM (2007) The salvador-warts-hippo pathway is required for epithelial proliferation and axis specification in Drosophila. Curr Biol 17, 1871-1878 https://doi.org/10.1016/j.cub.2007.09.062
- Zhang X, Milton CC, Humbert PO and Harvey KF (2009) Transcriptional output of the Salvador/warts/hippo pathway is controlled in distinct fashions in Drosophila melanogaster and mammalian cell lines. Cancer Res 69, 6033-6041
- Huang J, Wu S, Barrera J, Matthews K and Pan D (2005) The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122, 421-434 https://doi.org/10.1016/j.cell.2005.06.007
- Kango-Singh M and Singh A (2009) Singh, Regulation of organ size: insights from the Drosophila Hippo signaling pathway. Dev Dyn 238, 1627-1637 https://doi.org/10.1002/dvdy.21996
- Pan D (2007) Hippo signaling in organ size control. Genes Dev 21, 886-897 https://doi.org/10.1101/gad.1536007
- Zhang L, Yue T and Jiang J (2009) Hippo signaling pathway and organ size control. Fly (Austin) 3, 68-73 https://doi.org/10.4161/fly.3.1.7788
- Wang K, Degerny C, Xu M and Yang XJ (2009) YAP, TAZ, and Yorkie: a conserved family of signal-responsive transcriptional coregulators in animal development and human disease. Biochem Cell Biol 87, 77-91 https://doi.org/10.1139/O08-114
- Xu T, Wang W, Zhang S, Stewart RA and Yu W (1995) Identifying tumor suppressors in genetic mosaics: the Drosophila lats gene encodes a putative protein kinase. Development 121, 1053-1063
- Pantalacci S, Tapon N and Leopold P (2003) The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila. Nat Cell Biol 5, 921-927 https://doi.org/10.1038/ncb1051
- Jia J, Zhang W, Wang B, Trinko R and Jiang J (2003) The Drosophila Ste20 family kinase dMST functions as a tumor suppressor by restricting cell proliferation and promoting apoptosis. Genes Dev 17, 2514-2519 https://doi.org/10.1101/gad.1134003
- Udan RS, Kango-Singh M, Nolo R, Tao C and Halder G (2003) Hippo promotes proliferation arrest and apoptosis in the Salvador/Warts pathway. Nat Cell Biol 5, 914-920 https://doi.org/10.1038/ncb1050
- Piccolo S, Dupont S and Cordenonsi M (2014) The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev 94, 1287-1312 https://doi.org/10.1152/physrev.00005.2014
- Harvey KF, Zhang X and Thomas DM (2013) Thomas, The Hippo pathway and human cancer. Nat Rev Cancer 13, 246-257 https://doi.org/10.1038/nrc3458
- Yu FX, Zhao B and Guan KL (2015) Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell 163, 811-828 https://doi.org/10.1016/j.cell.2015.10.044
- Piccolo S, Cordenonsi M and Dupont S (2013) Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis. Clin Cancer Res 19, 4925-4930 https://doi.org/10.1158/1078-0432.CCR-12-3172
- Keren-Paz A, Emmanuel R and Samuels Y (2015) YAP and the drug resistance highway. Nat Genet 47, 193-194 https://doi.org/10.1038/ng.3228
- Jiao S, Wang H and Shi Z (2014) A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 25, 166-180 https://doi.org/10.1016/j.ccr.2014.01.010
- Steinhardt AA, Gayyed MF, Klein AP et al (2008) Expression of Yes-associated protein in common solid tumors. Hum Pathol 39, 1582-1589 https://doi.org/10.1016/j.humpath.2008.04.012
- Wang Y, Xie C, Li Q, Xu K and Wang E (2013) Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour Biol 34, 2169-2174 https://doi.org/10.1007/s13277-013-0751-x
- Camargo FD, Gokhale S, Johnnidis JB et al (2007) YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol 17, 2054-2060 https://doi.org/10.1016/j.cub.2007.10.039
- Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA and Sillje HH (2005) The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 24, 2076-2086 https://doi.org/10.1038/sj.onc.1208445
- Hao Y, Chun A, Cheung K, Rashidi B and Yang X (2008) Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem 283, 5496-5509 https://doi.org/10.1074/jbc.M709037200
- Zhao B, Ye X, Yu J et al (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22, 1962-1971 https://doi.org/10.1101/gad.1664408
- Flaherty KT, Hodi FS and Fisher DE (2012) From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 12, 349-361 https://doi.org/10.1038/nrc3218
- Eggermont AM and Robert C (2012) Melanoma in 2011: a new paradigm tumor for drug development. Nat Rev Clin Oncol 9, 74-76 https://doi.org/10.1038/nrclinonc.2011.201
- Jones PS and Jones D (2012) New regulatory framework for cancer drug development. Drug Discov Today 17, 227-231 https://doi.org/10.1016/j.drudis.2011.12.015
- Mullard A (2015) The Roadmap Epigenomics Project opens new drug development avenues. Nat Rev Drug Discov 14, 223-225 https://doi.org/10.1038/nrd4582
- Vukicevic S (2016) Current Challenges and Hurdles in New Drug Development. Clin Ther 38, e3
- De Angelis ML, De Maria R and Baiocchi M (2018) How to Assess Drug Resistance in Cancer Stem Cells. Methods Mol Biol 1692, 107-115
- Emery CM, Vijayendran KG, Zipser MC et al (2009) MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 106, 20411-20416 https://doi.org/10.1073/pnas.0905833106
- Guang MHZ, McCann A, Bianchi G et al (2018) Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. Leuk Lymphoma 59, 542-561 https://doi.org/10.1080/10428194.2017.1337115
- Norouzi-Barough L, Sarookhani MR, Sharifi M, Moghbelinejad S, Jangjoo S and Salehi R (2017) Molecular Mechanisms of Drug Resistance in Ovarian Cancer. J Cell Physiol [Epub ahead of print]
- Siegfried Z and Karni R (2017) The role of alternative splicing in cancer drug resistance. Curr Opin Genet Dev 48, 16-21
- Mansoori B, Mohammadi A, Davudian S, Shirjang S and Baradaran B (2017) The Different Mechanisms of Cancer Drug Resistance: A Brief Review. Adv Pharm Bull 7, 339-348 https://doi.org/10.15171/apb.2017.041
- Lin CH, Pelissier FA, Zhang H et al (2015) Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors. Mol Biol Cell 26, 3946-3953 https://doi.org/10.1091/mbc.E15-07-0456
- Lin L, Sabnis AJ, Chan E et al (2015) The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet 47, 250-256 https://doi.org/10.1038/ng.3218
- Guo L and Teng L (2015) YAP/TAZ for cancer therapy: opportunities and challenges (review). Int J Oncol 46, 1444-1452 https://doi.org/10.3892/ijo.2015.2877
- Moroishi T, Hansen CG and Guan KL (2015) The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 15, 73-79 https://doi.org/10.1038/nrc3876
- Ma Y, Yang Y, Wang F, Wei Q and Qin H (2015) Hippo-YAP signaling pathway: A new paradigm for cancer therapy. Int J Cancer 137, 2275-2286 https://doi.org/10.1002/ijc.29073
- Kim MH, Kim J, Hong H et al (2016) Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation. EMBO J 35, 462-478 https://doi.org/10.15252/embj.201592081
- Hsu PC, You B, Yang YL et al (2016) YAP promotes erlotinib resistance in human non-small cell lung cancer cells. Oncotarget 7, 51922-51933
- Zanconato F, Battilana G, Cordenonsi M and Piccolo S (2016) YAP/TAZ as therapeutic targets in cancer. Curr Opin Pharmacol 29, 26-33 https://doi.org/10.1016/j.coph.2016.05.002
- Andl T, Zhou L, Yang K, Kadekaro AL and Zhang Y (2017) YAP and WWTR1: New targets for skin cancer treatment. Cancer Lett 396, 30-41 https://doi.org/10.1016/j.canlet.2017.03.001
- Kim MH and Kim J (2017) Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies. Cell Mol Life Sci 74, 1457-1474 https://doi.org/10.1007/s00018-016-2412-x
- Sun PL, Jin Y and Chung JH (2017) Reply: YAP is a Key Factor to Improve the Management of Cancer Treatments. Ann Surg Oncol 24, 644-645 https://doi.org/10.1245/s10434-017-6205-8
- Zhang Y, Shen H, Withers HG et al (2017) VGLL4 Selectively Represses YAP-Dependent Gene Induction and Tumorigenic Phenotypes in Breast Cancer. Sci Rep 7, 6190 https://doi.org/10.1038/s41598-017-06227-7
- Ahmed AA, Mohamed AD, Gener M, Li W and Taboada E (2017) YAP and the Hippo pathway in pediatric cancer. Mol Cell Oncol 4, e1295127 https://doi.org/10.1080/23723556.2017.1295127
- Avril T and Chevet E (2015) Proteostasis trumps YAP in colon cancer. Sci Signal 8, fs18 https://doi.org/10.1126/scisignal.aad3123
- Cao L, Sun PL, Yao M, Jia M and Gao H (2017) Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues. Hum Pathol 68, 166-174 https://doi.org/10.1016/j.humpath.2017.08.032
- Eibl G and Rozengurt E (2017) YAP, and obesity in pancreatic cancer: A signaling network with multiple loops. Semin Cancer Biol [Epub ahead of print]
- Feng J, Gou J, Jia J, Yi T, Cui T and Li Z (2016) Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer. Onco Targets Ther 9, 5371-5381 https://doi.org/10.2147/OTT.S109979
- Kim HM, Jung WH and Koo JS (2015) Expression of Yes-associated protein (YAP) in metastatic breast cancer. Int J Clin Exp Pathol 8, 11248-11257
- Maugeri-Sacca M, Barba M, Pizzuti L et al (2015) The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. Expert Rev Mol Med 17, e14 https://doi.org/10.1017/erm.2015.12
- Zanconato F, Cordenonsi M and Piccolo S (2016) YAP/TAZ at the Roots of Cancer. Cancer Cell 29, 783-803 https://doi.org/10.1016/j.ccell.2016.05.005
- Zhou GX, Li XY, Zhang Q et al (2013) Effects of the hippo signaling pathway in human gastric cancer. Asian Pac J Cancer Prev 14, 5199-5205 https://doi.org/10.7314/APJCP.2013.14.9.5199
- Formisano L, Jansen VM, Marciano R and Bianco R (2017) From biology to therapy: Improvements of therapeutic options in Lung cancer. Anticancer Agents Med Chem [Epub ahead of print]
- Lemjabbar-Alaoui H, Hassan OU, Yang YW and Buchanan P (2015) Lung cancer: Biology and treatment options. Biochim Biophys Acta 1856, 189-210
- Suda K and Mitsudomi T (2017) [Molecular Biology for Surgical Treatment of Lung Cancer]. Kyobu Geka 70, 4-8
- Lee BS, Park DI, Lee DH et al (2017) Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. Biochem Biophys Res Commun 491, 493-499 https://doi.org/10.1016/j.bbrc.2017.07.007
- Lee JE, Park HS, Lee D et al (2016) Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. Biochem Biophys Res Commun 474, 154-160 https://doi.org/10.1016/j.bbrc.2016.04.089
- Karachaliou N, Chaib I, Pilotto S et al (2016) 76P An innovative co-targeting of signal transducer and activator of transcription 3 (STAT3) and Src-YAP pathways in EGFR mutant non-small cell lung cancer (NSCLC). J Thorac Oncol 11, S87-S88
- Wang H, Lu B, Castillo J et al (2016) Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling. J Biol Chem 291, 15256-15266 https://doi.org/10.1074/jbc.M116.722967
- Parsa Y, Mirmalek SA, Kani FE et al (2016) A Review of the Clinical Implications of Breast Cancer Biology. Electron Physician 8, 2416-2424 https://doi.org/10.19082/2416
- Chan SW, Lim CJ, Guo K et al (2008) A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 68, 2592-2598 https://doi.org/10.1158/0008-5472.CAN-07-2696
- Cordenonsi M, Zanconato F, Azzolin L et al (2011) The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147, 759-772 https://doi.org/10.1016/j.cell.2011.09.048
- Diaz-Martin J, Lopez-Garcia MA, Romero-Perez L et al (2015) Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. Endocr Relat Cancer 22, 443-454 https://doi.org/10.1530/ERC-14-0456
- Li YW, Shen H, Frangou C et al (2015) Characterization of TAZ domains important for the induction of breast cancer stem cell properties and tumorigenesis. Cell Cycle 14, 146-156 https://doi.org/10.4161/15384101.2014.967106
- Bartucci M, Dattilo R, Moriconi C et al (2015) TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene 34, 681-690 https://doi.org/10.1038/onc.2014.5
- Yuan M, Tomlinson V, Lara R et al (2008) Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 15, 1752-1759 https://doi.org/10.1038/cdd.2008.108
- Kim SK, Jung WH and Koo JS (2014) Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. Int J Clin Exp Pathol 7, 3224-3234
- Jaramillo-Rodriguez Y, Cerda-Flores RM, Ruiz-Ramos R, Lopez-Marquez FC and Calderon-Garciduenas AL (2014) YAP expression in normal and neoplastic breast tissue: an immunohistochemical study. Arch Med Res 45, 223-228 https://doi.org/10.1016/j.arcmed.2014.01.010
- Kagawa Y, Ishii H, Sekimoto M, Doki Y and Mori M (2011) [Molecular biology of colon cancer]. Nihon Rinsho 69, 67-71
- Zhang L and Yu J (2013) Role of apoptosis in colon cancer biology, therapy, and prevention. Curr Colorectal Cancer Rep 9
- Kim HB, Kim M, Park YS et al (2017) Prostaglandin E2 Activates YAP and a Positive-Signaling Loop to Promote Colon Regeneration After Colitis but Also Carcinogenesis in Mice. Gastroenterology 152, 616-630 https://doi.org/10.1053/j.gastro.2016.11.005
- Ling HH, Kuo CC, Lin BX, Huang YH and Lin CW (2017) Elevation of YAP promotes the epithelial-mesenchymal transition and tumor aggressiveness in colorectal cancer. Exp Cell Res 350, 218-225 https://doi.org/10.1016/j.yexcr.2016.11.024
- Lee KW, Lee SS, Kim SB et al (2015) Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. Clin Cancer Res 21, 357-364 https://doi.org/10.1158/1078-0432.CCR-14-1374
- Jerhammar F, Johansson AC, Ceder R et al (2014) YAP1 is a potential biomarker for cetuximab resistance in head and neck cancer. Oral Oncol 50, 832-839 https://doi.org/10.1016/j.oraloncology.2014.06.003
- Hernanda PY, Pedroza-Gonzalez A, Sprengers D, Peppelenbosch MP and Pan Q (2014) Multipotent mesenchymal stromal cells in liver cancer: implications for tumor biology and therapy. Biochim Biophys Acta 1846, 439-445
- Kudo M (2012) Targeted therapy for liver cancer: updated review in 2012. Curr Cancer Drug Targets 12, 1062-1072
- Oishi N, Yamashita T and Kaneko S (2014) Molecular biology of liver cancer stem cells. Liver Cancer 3, 71-84 https://doi.org/10.1159/000343863
- Kim Y and Jho EH (2017) Deubiquitinase YOD1: the potent activator of YAP in hepatomegaly and liver cancer. BMB Rep 50, 281-282 https://doi.org/10.5483/BMBRep.2017.50.6.078
- Liu AM, Xu MZ, Chen J, Poon RT and Luk JM (2010) Targeting YAP and Hippo signaling pathway in liver cancer. Expert Opin Ther Targets 14, 855-868 https://doi.org/10.1517/14728222.2010.499361
- Liu AM, Xu Z and Luk JM (2012) An update on targeting Hippo-YAP signaling in liver cancer. Expert Opin Ther Targets 16, 243-247 https://doi.org/10.1517/14728222.2012.662958
- Liu-Chittenden Y, Huang B, Shim JS et al (2012) Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 26, 1300-1305 https://doi.org/10.1101/gad.192856.112
- Yimlamai D, Fowl BH and Camargo FD (2015) Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer. J Hepatol 63, 1491-1501 https://doi.org/10.1016/j.jhep.2015.07.008
- Han SX, Bai E, Jin GH et al (2014) Expression and clinical significance of YAP, TAZ, and AREG in hepatocellular carcinoma. J Immunol Res 2014, 261365
- Cervantes A, Rodriguez Braun E, Perez Fidalgo A and Chirivella Gonzalez I (2007) Molecular biology of gastric cancer. Clin Transl Oncol 9, 208-215 https://doi.org/10.1007/s12094-007-0041-4
- Dreznik A, Purim O, Idelevich E et al (2012) Gastric cancer: biology and clinical manifestations in Israel. J Surg Oncol 105, 316-322 https://doi.org/10.1002/jso.22078
- El-Rifai W and Powell SM (2002) Molecular biology of gastric cancer. Semin Radiat Oncol 12, 128-140 https://doi.org/10.1053/srao.2002.30815
- Cai J, Zhang N, Zheng Y, de Wilde RF, Maitra A and Pan D (2010) The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. Genes Dev 24, 2383-2388 https://doi.org/10.1101/gad.1978810
- Zhou D, Zhang Y, Wu H et al (2011) Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci U S A 108, E1312- E1320 https://doi.org/10.1073/pnas.1110428108
- Kaan HYK, Chan SW, Tan SKJ et al (2017) Crystal structure of TAZ-TEAD complex reveals a distinct interaction mode from that of YAP-TEAD complex. Sci Rep 7, 2035 https://doi.org/10.1038/s41598-017-02219-9
- Zhang Z, Lin Z, Zhou Z et al (2014) Structure-Based Design and Synthesis of Potent Cyclic Peptides Inhibiting the YAP-TEAD Protein-Protein Interaction. ACS Med Chem Lett 5, 993-998 https://doi.org/10.1021/ml500160m
Cited by
- SAV1, regulated by microRNA-21, suppresses tumor growth in colorectal cancer pp.1208-6002, 2019, https://doi.org/10.1139/bcb-2018-0034